Issue 103

Senate Bill 5660

Washington’s Senate Bill 5660

For The Psychedelics as Medicine Report: Fourth Edition, PSYCH spoke with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

In March, the Washington State legislature passed Senate Bill 5660, directing Washington State Health Care Authority to assess the provision of psilocybin services.

State officials have created a working group to evaluate the socioeconomic benefits of an adult-use psilocybin programme.

This working group must deliver a preliminary report on its findings to the Washington State Governor by December, with a full report submitted by the end of 2023.

Assuming the results of the report are positive, psilocybin could be available in Washington as early as 2026.

READ MORE

RESEARCH INTO THE BIOSYNTHESIS OF PSILOCYBIN

With psilocybin-producing mushrooms found worldwide, researchers at University of Plymouth study their evolution.

Read More

DEA PROPOSES PRODUCTION QUOTAS FOR 2023

It is proposed mescaline production increases from 100 grams to 1,200 grams, and that 5-MeO-DMT synthesis doubles.

Read More

BUSINESS AND INVESTMENT

Small Pharma releases Q2 2022 financial results.

COMPASS Pathways announces Phase III study design.

Empyrean Neuroscience launches with US$22m in funding.

Clairvoyant gets approval for alcohol-use disorder study.

Democratising access to psychedelic-assisted therapy.

Silo Wellness closes acquisition of Dyscovry.

atai shares data from study into opioid use disorder.

SCIENCE AND RESEARCH

Psilocybin-assisted therapy to be studied in the treatment of cannabis-use disorder.

Ketamine as a fast-acting antidepressant.

Observational study of treatment-resistant depression.

Protocol for placebo-controlled study to reduce alcohol use.

The UK has been at the forefront of psychedelic research since the 20th century ~ with this present era of discovery dubbed ‘the psychedelic renaissance’.

At PSYCH Symposium, Amanda Feilding, Executive Director at Beckley Foundation, discussed the resurgence of psychedelic science and the evolution of Beckley Foundation in a very special conversation with her son, Cosmo Feilding Mellen, CEO at Beckley Psytech.

REGULATION AND LEGISLATION

The regulation of psychedelic medicines in Canada.

Psilocybin-assisted therapy advocacy ramps up in Jamaica.

ARTICLES OF INTEREST

£35.4m to improve mental healthcare in the UK.

Investors expecting Europe-wide recession.

Goldman Sachs expects worse UK recession in 2023.

Partner with us